北京市发改委:公立医院都将推进医药分开

2016-01-26 王子薇 蒲长廷 健康界

摘要:2016年,在9000多项医药服务价格项目中,将先期放开500多项体现个性化需求的服务项目,并在体现医护人员技术劳务价值的服务项目方面,加快医疗服务价格改革。 在昨天下午进行的人代会通州团审议小组会中,北京市市委书记郭金龙亲临通州团听取代表们的意见和建议。在陈学明代表提到的百姓看病难、通州区床位不足等问题时,郭金龙表示行政副中心将改扩建一批医疗机构,形成多个医疗中心的布局。

摘要:2016年,在9000多项医药服务价格项目中,将先期放开500多项体现个性化需求的服务项目,并在体现医护人员技术劳务价值的服务项目方面,加快医疗服务价格改革。

在昨天下午进行的人代会通州团审议小组会中,北京市市委书记郭金龙亲临通州团听取代表们的意见和建议。在陈学明代表提到的百姓看病难、通州区床位不足等问题时,郭金龙表示行政副中心将改扩建一批医疗机构,形成多个医疗中心的布局。

陈学明代表在发言时表示,“十三五”期间潞河医院的日门诊量突破7000多人次,“超过一万就像赶集,要建立分级诊疗。医疗机构有通州的,市属的,这些部门人财物的归属,希望考虑整合建制后迁到通州的南部。”他说,目前潞河医院已经建立了心梗绿色通道,心梗支架手术已经完全可以操作,病人病发到手术完毕两个小时内抢救完成,医疗卫生状况得到明显改善。

陈学明说,十二五规划中,百姓看病难得到较大程度改善。而目前通州的问题是,床位依然不足,人均床位低于全市平均率,医疗卫生水平也存在不足,急需引进优质医疗资源,而且目前优秀专业技术人员短缺。

郭金龙对此表示,行政副中心将改扩建一批医疗机构,形成多个医疗中心的布局,作为行政副中心的支撑。“首医大(附属医院)、新华医院就要盖好了,安贞医院、中医院、东直门医院也要过去建立分院,再加上一些社会医疗机构,你的这个问题应该可以放心。”郭金龙说。
一名企业代表提出,行政副中心建立后,企业家既知道呆不住,又不想走。政府加大行政检查力度,特别引进市场化手段。企业被疏解后的土地再利用问题,符合北京的新定位。北京疏解后要搞高端产业,因为传统的厂房已经不适合科技产业。郭金龙表示,疏解功能的配套专项政策值得研究,需要加强监管。

市长王安顺参加西城团审议回应医疗服务价格要“三升三降”的建议时表示——今年要启动医疗价格体系改革

昨天,市长王安顺出席人大西城团审议时表示,今年北京一定要启动医疗价格体系改革。

市人大代表、北京大学第一医院院长刘玉村在会上建议,针对目前的医疗服务价格,他建议要“三升三降”。“三升”为提高挂号费、床位费和手术费。

他认为,这样可以疏导一些小病患者去社区医院看病,减少不必要的住院,以及体现医生的价值。“三降”包括降低药费、耗材费及检查费。刘玉村表示,减少与外企谈判、减少中间环节有望实现“三降”。
王安顺对此回应说,今年一定要启动医疗价格体系改革。“还有部队医院、国家卫计委的医院,医疗资源分布在不同层面,我们的政策统筹不了这些医院。所以改革一定要有精确化的管理办法,分清轻重缓急。”王安顺说。

市发改委主任卢彦透露——公立医院都将推进医药分开

昨日,在市十四届人大四次会议西城团三组的小组审议时,市发改委主任卢彦透露,今年,在9000多项医药服务价格项目中,将先期放开500多项体现个性化需求的服务项目,并在体现医护人员技术劳务价值的服务项目方面,加快医疗服务价格改革。

同时,急救系统120、999的价格改革和中医药价格改革,今年也有望先行一步。2012年,全市有5家公立医院率先试点医药分开的改革,实施药品零加价。

“但是这5家试点,现在也面临一些问题。”卢彦说,“因为只有这5家实行药品零加价,所以有病人在别家看病后来这5家取药”。

对于这样的“窘境”,卢彦表示,今年,本市所有公立医院都将加入医改,推进实施医药分开,目前已初步确定方案。

作为公立医院改革试点之一的积水潭医院,院长田伟在西城全团讨论会上提出,“过去以药养医是个历史问题,现在简单分割开,劳动收入却没有相应提高,医院会亏损。去年积水潭医院亏损了1个亿,比如手术等价格,70%以上都达不到保本”。

针对公立医院改革中面临的问题,卢彦透露,今年也将先期放开500多项医疗服务价格。“医药分开后,‘药’不挣钱、零加价,‘医’就要体现好医护人员的服务价值”。

“北京一共涉及9000项医药价格,政府人员是不可能完全熟知每个医疗服务项目的各个程序和方法,所以测算时还得听医院的。”卢彦介绍,下一步医院在疏解工作中,也将依靠经济手段来保障。

据介绍,北京城六区目前有88家三甲医院,诊疗量约2.2亿人,70%的患者来自外地,“城六区约1.54亿的流动诊疗人口,所以优质医院还需要从城里往外输出。”卢彦介绍说,北京三甲医院有准备去顺义的,平谷、密云、怀柔、顺义等东北方向居民,可以就近看病。同时,北京儿童医院托管保定医院,也将为疏解做重要的支撑,“以后保定、石家庄的儿童患者,可以在保定看病,享受北京的三甲医院水平。”

(原标题:北京通州布局多个医疗中心 今年启动医疗价格体系改革)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (22)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-28 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-28 胖胖7598

    要考虑多方利益

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-28 胖胖7598

    配套政策也要有

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 lpapple

    提高明收入

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 文医生

    待遇啊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    加薪才是王道

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 doctording1

    这篇文章有一定深度

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1636329, encodeId=38c51636329b3, content=<a href='/topic/show?id=56f63e8706d' target=_blank style='color:#2F92EE;'>#发改委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37870, encryptionId=56f63e8706d, topicName=发改委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=569522619490, createdName=ms6519009802973839, createdTime=Thu Jun 09 12:42:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534901, encodeId=3653153490184, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408720, encodeId=b4761408e2075, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 28 08:42:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61723, encodeId=dd9361e2343, content=要考虑多方利益, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:08:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61722, encodeId=78d361e220f, content=配套政策也要有, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Thu Jan 28 08:07:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60945, encodeId=b07a60945ec, content=提高明收入, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d9077449, createdName=lpapple, createdTime=Wed Jan 27 17:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60873, encodeId=c2c0608e39f, content=待遇啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 14:39:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60498, encodeId=4b3f60498d1, content=加薪才是王道, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:14:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60495, encodeId=b73d60495a1, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60404, encodeId=4ffa6040422, content=oo, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:42:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 mingliqinmian

    oo

    0

相关资讯

发改委低价药目录公布530种药物(图)

公布的低价药品清单包含化药品种280个、中成药品种250个,共530个品种1154个剂型。 李嘉诚增10亿扩产低价药 不少企业早已有准备。昨日广药白云山向记者介绍,李嘉诚旗下白云山和黄中药的主打品种复方丹参片、板蓝根等均入选该目录,企业决定斥资10亿元扩建原材料种植基地和生产车间。 事实上,近两年来,医院和药店药品断货现象不断,低价药“中标死”屡屡曝光,一些药企在